Palvella Therapeutics, Inc (PVLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has a cash flow conversion efficiency ratio of -0.047x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.86 Million) by net assets ($232.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PVLA days of operational coverage to measure how many days the company can operate on defensive assets alone.
Palvella Therapeutics, Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Palvella Therapeutics, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Palvella Therapeutics, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palvella Therapeutics, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Wanma Co Ltd
SHE:002276
|
0.009x |
|
Astra Microwave Products Limited
NSE:ASTRAMICRO
|
-0.078x |
|
Lanzhou LS Heavy Equipment Co
SHG:603169
|
-0.003x |
|
Lao Feng Xiang Co Ltd A
SHG:600612
|
-0.144x |
|
nCino Inc
NASDAQ:NCNO
|
0.083x |
|
GIMV NV
BR:GIMB
|
-0.025x |
|
S&T Bancorp Inc
NASDAQ:STBA
|
0.026x |
|
E-Mart
KO:139480
|
0.069x |
Annual Cash Flow Conversion Efficiency for Palvella Therapeutics, Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Palvella Therapeutics, Inc from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Palvella Therapeutics, Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.98 Million | $-25.01 Million | -0.894x | -416.11% |
| 2024-12-31 | $62.61 Million | $-10.84 Million | -0.173x | -104.90% |
| 2023-12-31 | $-3.88 Million | $-13.70 Million | 3.532x | +451.51% |
| 2022-12-31 | $-23.17 Million | $-14.84 Million | 0.640x | +524.31% |
| 2021-12-31 | $50.76 Million | $-7.66 Million | -0.151x | +89.80% |
| 2020-12-31 | $31.03 Million | $-45.90 Million | -1.479x | -- |
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more